Comparison of immunomodulatory treatments for multiple sclerosis

被引:1
作者
Durelli, L [1 ]
Clerico, M [1 ]
机构
[1] Univ Turin, Turin, Italy
关键词
CONSORT guidelines; glatiramer acetate; immunomodulatory treatment; interferon-beta; multiple sclerosis; randomized controlled trials;
D O I
10.1111/j.1468-1331.2005.01372.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:915 / 915
页数:1
相关论文
共 9 条
[1]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[2]  
Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
[3]   Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].
Durelli, L ;
Verdun, E ;
Barbero, P ;
Bergui, M ;
Versino, E ;
Ghezzi, A ;
Montanari, E ;
Zaffaroni, M .
LANCET, 2002, 359 (9316) :1453-1460
[4]   Twenty-four-month comparison of immunomodulatory treatments -: a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®) [J].
Haas, J ;
Firzlaff, M .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (06) :425-431
[5]  
HARMAN RJ, 2003, PHARM J, V270, P653
[6]  
JUNI P, 2000, P 3 S SYST REV BAS S, V19, P19
[7]  
Kappos L, 2004, MULT SCLER, V10, pS247
[8]   Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study [J].
Khaw, KT ;
Bingham, S ;
Welch, A ;
Luben, R ;
Wareham, N ;
Oakes, S ;
Day, N .
LANCET, 2001, 357 (9257) :657-663
[9]   Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].
Panitch, H ;
Goodin, DS ;
Francis, G ;
Chang, P ;
Coyle, PK ;
O'Connor, P ;
Monaghan, E ;
Li, D ;
Weinshenker, B .
NEUROLOGY, 2002, 59 (10) :1496-1506